An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors

news-events

Satya presents 2 e-posters at the AACR Annual Meeting

Poster 6368: “Discovery of potent, orally bioavailable, SOS1 inhibitors for KRAS-driven tumors” Abstract   KRAS is an oncogene implicated in a wide variety of tumors (~21% of solid tumors harbor KRAS mutations). KRAS interaction with Guanidine Exchange Factors (GEFs) is crucial for its activation, with SOS1 being the predominant GEF. SOS1 inhibition is thus expected

Satya presents 2 e-posters at the AACR Annual Meeting Read More »

Satya presents poster on its RAD51-BRCA2 disruptor program at AACR, New Orleans April 8-13

Poster #LBA041: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer, October 7-10, 2021 The DNA damage response (DDR) is a complex cellular network that acts as a cell defense mechanism and exerts signal for repair of DNA lesions. It repairs different types of DNA damage such as single-strand (ssDNA) breaks, DNA inter-strand crosslinks and

Satya presents poster on its RAD51-BRCA2 disruptor program at AACR, New Orleans April 8-13 Read More »

Scroll to Top